Med.Over.Net

Matične celice

Odgovarjajo: Milan Milošević, dr. med. spec. ortoped i traumatolog, Poliklinika Ribnjak d.o.o.

Vse o matičnih celicah, bankah matičnih celic, shranjevanju matičnih celic, regenerativni medicini in zdravljenju z matičnimi celicami. Na vaša vprašanja odgovarjata slovenski in hrvaški strokovnjak.

Milan Milošević , dr. med. spec. ortoped i traumatolog, Poliklinika Ribnjak d.o.o.

dr_Milosevic

matične celice in avtizem

Default avatar

miran1

Pozdravljeni.

V zadnjem času so bili nekateri uspešni poskusi terapije z matičnimi celicami pri otrocih z avtizmom. Zato me zanima, kakšne so možnosti pri nas, da bi poskusili s to metodo, saj je to očitno edino upanje za zdravljenje avtizma, posebej v slovenskem zdravstvu?
Default avatar

prozman

Dobro vprašanje. Čeprav imajo matične celice pomembno funkcijo pri razvoju živčevja, ki je v primeru avtizma prizadeto na različne načine, so primeri izboljšanja avtizma po presaditvi krvotvornih matičnih celic le anekdotični in niso pravilo.
Zatorej bi bilo preveč optimistično pričakovati hitrega zdravila na račun uporabe matičnih celic. Predvsem ne obstojajo znanstveno kredibilne študije, zato lahko rečemo, da je tako zdravljenje najmanj vprašljivo. To pa ne pomeni, da čez 10 let ne bo taka terapija spoznana za učinkovito.

Klinične študije s področja matičnih celic so izjemno drage. Če bodo dokazale, da je tako zdravljenje uspešno, bo verjetno kmalu dostopno tudi slovenskim bolnikom.
Default avatar

Ana23

Pozdravljeni


Mene pa zanima, ali potekajo kakšne študije tudi pri nas ali se le te opravljajo samo v tujini?

Hvala
Default avatar

prozman

Pri nas ni teh raziskav. Lahko pa si ogledate spodnji članek in internetno stran v Ameriki, kjer si metoda šele utira pot: http://www.cordblood.com/regenerative-medicine/autism. Sklep je lahko, da je zdravljenje avtizma z matičnimi celicami trenutno šele hipotetično in v fazi iniciative.
Prilagam citat s spleta, na žalost v angleščini:


Dear Families of Cord Blood Registry,
We regularly receive questions from clients about the status of cord blood stem research and autism and want to provide this update.
For those of you who have a child with autism, you already know that it is the most prevalent childhood developmental disorder. As you may have seen in the news this month, a study published in Pediatrics, the American Academy of Pediatrics' journal found that the parent-reported autism prevalence rate was one in every 91 American children. Another report expected later this year from the Centers for Disease Control (CDC) estimates that one in 100 children have been diagnosed with autism spectrum disorder (ASD) by 8-years of age. This is up from the 2007 estimated prevalence of one in 150. This new estimate means that approximately 673,000 U.S. children have autism.
Autism has been dubbed "an urgent public heath concern" by the CDC and it's no surprise that hundreds of organizations are dedicated to supporting new autism research. Despite this focus, we are not currently aware of any active or planned clinical trials to treat autism with stem cells. While there have been therapies proposed using cord blood stem cells and anecdotal evidence from a few clinics outside of the U.S. describing the use of stem cells to treat autism, none of these treatments have been validated. Because the underlying cause or causes of autism are not fully understood, researchers face significant obstacles in developing research study models using stem-cell based therapies.
However, we at Cord Blood Registry believe we may be able to help advance potential stem cell-based research for autism by taking an important first step: identifying individuals who have access to their own cord blood stem cells AND who have been diagnosed with an ASD. Based on the most recent statistics, there could be more than 3,200 children with ASD whose cord blood is stored with CBR. This is a substantial patient population that could interest researchers.
If you have a child diagnosed with a form of ASD and would like to be notified in the event that a researcher is considering a trial and interested in contacting you, we encourage you to register with CBR's Center for Regenerative Medicine here: http://www.cordblood.com/regenerative-medicine/autism. Please note: no personal information will be shared without written permission from you.
We want to emphasize that while we are not aware of any U.S. clinical trial in development today, we are committed to keeping you informed about any significant advancements in research or potential clinical trial opportunities.
Sincerely,
Heather Brown, M.S., C.G.C.
Vice President, Scientific & Medical Affairs
Cord Blood Registry